Lung injury of the neonate is a nosological entity that particularly affects preterm infants (e.g. <28 wks GA and <1000 g). Lung damage may start during pregnancy, but is realized especially during the first weeks of life. It can be responsible for long-term adverse outcomes.
The pathogenesis of lung injury is multifactorial, and prevention and management of the different pathological events (both in prenatal and postnatal life) are crucial to trying to reduce or limit the occurrence of lung damage. The different aspects involved in the development of lung injury are listed below.
1) Lung injury in the neonate: definition and pathogenesis (lung structural damage is due to numerous antenatal and postnatal factors that can trigger or facilitate a similar inflammatory pathway: lung growth interruption due to premature birth or fetal growth restriction, genetic factors, intrauterine or postnatal infections, pressure and volume during respiratory support after birth, post-natal high levels of oxygen exposure, etc.)
2) The pivotal role of the complicated pregnancy in the occurrence of neonatal lung injury (e.g. chorioamnionitis, IUGR, PPROM, etc.)
3) Delivery room transition and lung injury prevention
4) A gentle respiratory strategy in NICU to limit the risk of lung injury and bronchopulmonary dysplasia (BPD) development
5) Strategies to optimize surfactant therapy (timing and modality of administration)
6) Role of patent ductus arteriosus (PDA), neonatal infections, and nutrition on neonatal lung injury occurrence
7) BPD as one of the most important long-term adverse outcomes of neonatal lung injury
8) Role of steroids in the prevention and treatment of infants with BPD
9) Short- and long-term respiratory follow-up of BPD infants into adulthood.
The authors, according to the most recent evidence in literature, good clinical practice and ongoing research projects, will contribute articles to describe the different aspects of lung injury pathogenesis, prevention, management, and long-term follow-up.
Research Topic editor GM Schmölzer co-owns company RETAIN Labs Medical Inc. All other Research Topic editors declare no competing interests.
Lung injury of the neonate is a nosological entity that particularly affects preterm infants (e.g. <28 wks GA and <1000 g). Lung damage may start during pregnancy, but is realized especially during the first weeks of life. It can be responsible for long-term adverse outcomes.
The pathogenesis of lung injury is multifactorial, and prevention and management of the different pathological events (both in prenatal and postnatal life) are crucial to trying to reduce or limit the occurrence of lung damage. The different aspects involved in the development of lung injury are listed below.
1) Lung injury in the neonate: definition and pathogenesis (lung structural damage is due to numerous antenatal and postnatal factors that can trigger or facilitate a similar inflammatory pathway: lung growth interruption due to premature birth or fetal growth restriction, genetic factors, intrauterine or postnatal infections, pressure and volume during respiratory support after birth, post-natal high levels of oxygen exposure, etc.)
2) The pivotal role of the complicated pregnancy in the occurrence of neonatal lung injury (e.g. chorioamnionitis, IUGR, PPROM, etc.)
3) Delivery room transition and lung injury prevention
4) A gentle respiratory strategy in NICU to limit the risk of lung injury and bronchopulmonary dysplasia (BPD) development
5) Strategies to optimize surfactant therapy (timing and modality of administration)
6) Role of patent ductus arteriosus (PDA), neonatal infections, and nutrition on neonatal lung injury occurrence
7) BPD as one of the most important long-term adverse outcomes of neonatal lung injury
8) Role of steroids in the prevention and treatment of infants with BPD
9) Short- and long-term respiratory follow-up of BPD infants into adulthood.
The authors, according to the most recent evidence in literature, good clinical practice and ongoing research projects, will contribute articles to describe the different aspects of lung injury pathogenesis, prevention, management, and long-term follow-up.
Research Topic editor GM Schmölzer co-owns company RETAIN Labs Medical Inc. All other Research Topic editors declare no competing interests.
